The Drug Industry Might Have Dodged A Build Back Better Bullet But Remains In Congressional Crosshairs

The Biden administration’s campaign to rehabilitate the drug price negotiation legislation contained in the stalled Build Back Better bill (BBB), appears to have been sidelined for now. Reluctant senators and Covid-19 have all but eliminated any new year’s momentum to pass it. With time running out, it’s tempting to believe that the drug industry has dodged another bullet by having these provisions go nowhere for the time being. That presumption would be short-sighted.

Read the source article at forbes.com
2022-01-17 00:00:00